Factor Xa inhibitors

Known as: Inhibitors, Factor Xa 
Endogenous factors and drugs that inhibit or block the activity of FACTOR XA.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
BACKGROUND Andexanet alfa (andexanet) is a recombinant modified human factor Xa decoy protein that has been shown to reverse the… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
Review
2015
Review
2015
Three factor Xa inhibitors have been studied in the treatment of venous thromboembolism, both for acute therapy and as extended… (More)
  • table 1
  • table 2
Is this relevant?
Review
2012
Review
2012
Vitamin K antagonists, such as warfarin, have been the mainstay of oral anticoagulation for many decades. Although effective… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
Review
2011
Review
2011
BACKGROUND The activation of coagulation mechanisms plays a central role in the pathogenesis of acute coronary syndromes (ACS… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2010
2010
Venous thromboembolism is the third leading cause of cardiovascular death, after myocardial infarction and stroke.1 Total hip or… (More)
Is this relevant?
2010
2010
Direct factor Xa inhibitors are among the compounds at the forefront of clinical development for the prevention and treatment of… (More)
  • figure 1
Is this relevant?
2009
2009
BACKGROUND Apixaban is an oral, direct factor Xa (FXa) inhibitor in late-stage clinical development. This study assessed effects… (More)
  • figure 2
  • figure 1
  • figure 3
  • figure 4
Is this relevant?
Review
2007
Review
2007
Anticoagulants are recommended for the prevention and treatment of a wide variety of thromboembolic events. Although existing… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
Review
2002
Review
2002
Despite currently available antithrombotic therapies, venous thromboembolism (VTE) remains a major cause of morbidity and… (More)
Is this relevant?
2002
2002
DPC423 [1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5… (More)
  • figure 2
  • figure 3
  • figure 4
  • figure 5
  • figure 7
Is this relevant?